Molina Healthcare stock rating downgraded by Morgan Stanley on utilization concerns

Molina Healthcare (NYSE:MOH) faces significant financial headwinds due to increased healthcare utilization and rising medical costs, prompting a downward revision of its full-year 2025 EPS guidance to $21.50-$22.50 from previous estimates of at least $24.50, alongside a pre-announced lower Q2 2025 EPS of $5.50. In response, Morgan Stanley downgraded MOH to Equalweight and sharply cut its price target to $266 from $364, citing elevated medical loss ratio estimates, while UBS and Barclays also reduced their price targets. The stock is currently trading near its 52-week low, reflecting broad analyst concerns despite Cantor Fitzgerald maintaining an Overweight rating.

Analysis

Molina Healthcare (MOH) is facing significant fundamental pressure stemming from increased healthcare utilization, which has triggered a material downward revision of its financial outlook. The company pre-announced a Q2 2025 earnings per share of $5.50, missing the consensus estimate of $6.20, and sharply cut its full-year 2025 EPS guidance to a range of $21.50-$22.50, down from a prior floor of $24.50. This revision is attributed to rising medical costs across all its key segments—Medicaid, Medicare, and the ACA marketplace—which are expected to persist. The market response has been decidedly negative, with the company's stock trading near its 52-week low. Reflecting these challenges, Morgan Stanley downgraded MOH to Equalweight and slashed its price target to $266, basing the valuation on a 10.7x P/E multiple of 2026 estimates. The downgrade was supported by specific increases in medical loss ratio (MLR) forecasts, with Medicaid MLR raised to 90.3% and Medicare MLR to 89.5%. This bearish sentiment is echoed by UBS and Barclays, which also lowered their price targets to $260 and $270 respectively, while maintaining neutral ratings. Although Cantor Fitzgerald remains an outlier with an Overweight rating and a $356 price target, the broad consensus among analysts points to deteriorating profitability and heightened operational risk.

Key Decisions for Investors

• Given the significant cut in 2025 earnings guidance and persistent medical cost pressures, investors should recognize the heightened risk profile and potential for continued stock underperformance until utilization trends stabilize.
• Closely monitor Molina's forthcoming quarterly reports, paying specific attention to the Medical Loss Ratios (MLRs) to verify if the company can manage costs within the newly elevated analyst projections.
• While the stock is trading near its 52-week low, this reflects a fundamental deterioration, and any consideration of a position should weigh whether the current valuation adequately prices in the risk of sustained margin compression.
• The consensus among analysts is overwhelmingly cautious; the lone Overweight rating from Cantor Fitzgerald represents a contrarian view that should be carefully evaluated against the negative revisions from multiple other investment banks.